| Drug General Information |
| Drug ID |
D0D8SN
|
| Former ID |
DIB001913
|
| Drug Name |
ALD-401
|
| Synonyms |
ALD-401, Aldagen; ALDH-expressing stem cell therapy (ischemic stroke), Aldagen
|
| Indication |
Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63]
|
Phase 2 |
[1]
|
|---|
| Company |
Cytomedix
|
| Target and Pathway |
| Target(s) |
Aldehyde dehydrogenase, mitochondrial |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
Glycolysis / Gluconeogenesis
|
|
Pentose and glucuronate interconversions
|
|
Ascorbate and aldarate metabolism
|
|
Fatty acid degradation
|
|
Valine, leucine and isoleucine degradation
|
|
Lysine degradation
|
|
Arginine and proline metabolism
|
|
Histidine metabolism
|
|
Tryptophan metabolism
|
|
beta-Alanine metabolism
|
|
Glycerolipid metabolism
|
|
Pyruvate metabolism
|
|
Metabolic pathways
|
|
Biosynthesis of antibiotics
|
|
PathWhiz Pathway
|
Beta-Alanine Metabolism
|
|
Ethanol Degradation
|
|
Histidine Metabolism
|
|
Valine, Leucine and Isoleucine Degradation
|
|
Pyruvate Metabolism
|
|
Oxidation of Branched Chain Fatty Acids
|
|
Glycine and Serine Metabolism
|
|
Tryptophan Metabolism
|
|
WikiPathways
|
Tryptophan metabolism
|
|
Fatty Acid Omega Oxidation
|
|
Phase 1 - Functionalization of compounds
|
|
Neurotransmitter Clearance In The Synaptic Cleft
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01273337) Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects. U.S. National Institutes of Health. |
|---|
| REF 2 | A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo. Clin Cancer Res. 2011 Dec 1;17(23):7265-72. |
|---|
